Sodium control in aneurysmal subarachnoid haemorrhage

The effect of fludrocortisone plus standard care on sodium control in aneurysmal subarachnoid haemorrhage

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000999730

Acronym

Sodium control in SAH

Enrollment

Registered

2013-09-10

Start date

2016-10-05

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hyponatremia, which describes low blood sodium levels, occurs frequently in patients who are in the hospital after aneurysmal subarachnoid haemorrhage, a condition where there has been bleeding in the brain. Hyponatremia can cause confusion and seizures, and possibly long term effects on a patient’s ability to function. A substantial amount of resources are used in treating this condition. This study looks at determining whether a medication called fludrocortisone can help in reducing the severity and duration of hyponatremia in this setting.

Interventions

Fludrocortisone 100mcg oral tablet twice daily in addition to standard care until hyponatremia resolves per twice daily serum electrolytes Adherence ensured by tablets being administered by nursing staff on hospital ward

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

Inclusion: * D1-18 aneurysmal SAH * Serum Na <135mmol/L

Exclusion criteria

Exclusion: * Thyroid abnormality * Cortisol abnormality * Pre-morbid cardiopulmonary disease * Pre-morbid electrolyte imbalance * Pre-morbid treated hypertension * Pre-morbid systemic fungal infection * Women who are pregnant * Children and/or young people (<18 years) * Aged (>80 years)

Outcome results